First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks — FEATURE

Moderate to Severe Plaque-type Psoriasis Clinical Trial

Official title:
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

Status Completed

Clinical Trial Summary

The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Moderate to Severe Plaque-type Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT01555125
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	May 8, 2012
Completion date	October 24, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01365455` - Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year	Phase 3
Completed	`NCT01544595` - Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab	Phase 3
Completed	`NCT02474069` - Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis	Phase 3
Completed	`NCT01406938` - Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens	Phase 3